Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LYR-220 Design 1 · 1 trial · 2 indications
Product-related unexpected serious adverse events
Plasma MF concentrations at 1 hour post study treatment administration and at Days 2 or 3, days 5 or 8, and Weeks 4,12,16 or 20, 24 and 25. The PK analysis will be performed based on subjects with available plasma MF concentration data post Day 1 administration procedure.
| Arm | Type | Description |
|---|---|---|
| Part 1: Treatment Arm LYR-220 Design 1 | EXPERIMENTAL | Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1 |
| Part 1 and Part 2: Treatment Arm LYR-220 Design 2 | EXPERIMENTAL | Bilateral insertion of LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2 |
| Part 2: Treatment Arm Bilateral sham procedure control | SHAM_COMPARATOR | Bilateral sham procedure control |
| Name | Type | Description |
|---|---|---|
| LYR-220 Design 1 (Part 1 only) | DRUG | LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1 |
| LYR-220 Design 2 (Part 1 and Part 2) | DRUG | LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2 |
| Bilateral sham procedure control (Part 2) | DRUG | Bilateral sham procedure control |
Inclusion Criteria: * Diagnosis of chronic rhinosinusitis. * Has had a prior bilateral total ethmoidectomy. * Has computed tomography (CT) ethmoid cavity opacification. * Has a Sinonasal Outcome Test (SNOT-22) ≥ 20 at Screening Visit. * Minimum cardinal symptom score. * Has been informed of the nat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE3 | Itepekimab |
| AstraZeneca PLC | AZN | 4 | PHASE3 | Tezepelumab |
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
LYR-220 Design 1 is an investigational small molecule being developed for chronic sinusitis, specifically chronic rhinosinusitis in adults. It is delivered locally to the sinuses. The drug is currently in clinical development and has not been approved by regulatory authorities.
LYR-220 Design 1 is being developed by Lyra Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker LYRA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with chronic sinusitis.
LYR-220 Design 1 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied for the treatment of chronic sinusitis in adult patients.
LYR-220 Design 1 has one completed Phase 2 clinical trial, the BEACON study (NCT05035654). This trial enrolled 48 adult participants with chronic rhinosinusitis across the United States and Australia. The study was sham-controlled and randomized, though it was not double-blinded.
LYR-220 Design 1 is a specific formulation or version of the drug candidate LYR-220. The designation 'Design 1' distinguishes this particular variant in clinical testing. The drug is being developed by Lyra Therapeutics for chronic sinusitis.